Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Moleculin Biotech (MBRX) Return on Capital Employed (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Return on Capital Employed data on record, last reported at 1.58% in Q3 2025.

  • For Q3 2025, Return on Capital Employed fell 5.0% year-over-year to 1.58%; the TTM value through Sep 2025 reached 1.58%, down 5.0%, while the annual FY2024 figure was 1.2%, 48.0% down from the prior year.
  • Return on Capital Employed reached 1.58% in Q3 2025 per MBRX's latest filing, up from 1.9% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.23% in Q2 2021 and bottomed at 2.15% in Q1 2025.
  • Average Return on Capital Employed over 5 years is 0.89%, with a median of 0.7% recorded in 2023.
  • Peak YoY movement for Return on Capital Employed: skyrocketed 51bps in 2021, then plummeted -119bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.28% in 2021, then crashed by -95bps to 0.54% in 2022, then crashed by -71bps to 0.92% in 2023, then crashed by -95bps to 1.8% in 2024, then rose by 12bps to 1.58% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Capital Employed were 1.58% in Q3 2025, 1.9% in Q2 2025, and 2.15% in Q1 2025.